Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma
Cancer Epidemiol Biomarkers, July 30, 2020 (Epub ahead of print) [Link]
Ferdinando Cerciello, et.al.
Background: We have verified a mass spectrometry (MS) based targeted proteomics signature for the detection of malignant pleural mesothelioma (MPM) from the blood. Methods: A seven-peptide biomarker MPM signature by targeted proteomics in serum was identified in a previous independent study. Here, we have verified the predictive accuracy of a reduced version of that signature, now composed of six-peptide biomarkers. We have applied liquid chromatography-selected reaction monitoring (LC-SRM), also known as multiple reaction monitoring (MRM), for the investigation of 402 serum samples from 213 MPM patients and 189 cancer-free asbestos exposed donors from the USA, Australia and Europe.